Related Experiment Video
Updated: Jun 26, 2025

04:41
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
Semantic Harmonization of Alzheimer's Disease Datasets Using AD-Mapper
Philipp Wegner1,2,3, Helena Balabin4,5, Mehmet Can Ay1,6
1Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany.
Journal of Alzheimer'S Disease : JAD
|May 17, 2024
Summary
We developed AD-Mapper, an automatic tool for harmonizing Alzheimer's disease (AD) cohort studies. This tool significantly improves data consistency for better cross-cohort analysis.
Area of Science:
- Biomedical Informatics
- Computational Biology
- Neuroscience Data Science
Background:
- Semantic harmonization of Alzheimer's disease (AD) cohort studies remains a challenge.
- Existing methods lack automated solutions for cross-cohort data integration.
- Data-driven analysis in AD research relies heavily on harmonized cohort data.
Purpose of the Study:
- To accelerate the semantic harmonization of AD cohort studies.
- To develop an automated tool for improving cross-cohort analysis.
- To enhance data consistency and comparability across diverse AD datasets.
Main Methods:
- Created a common data model (CDM) by cross-mapping data from 20 cohorts, three CDMs, and ontology terms.
- Fine-tuned a BioBERT model using the developed CDM.
- Evaluated the model's performance on three unseen cohorts against a string-matching baseline.
Main Results:
- Introduced AD-Mapper, an interface for automatic harmonization of AD cohort studies.
- AD-Mapper demonstrated superior performance compared to a string-matching baseline on unseen cohorts.
- Showcased a comprehensive CDM containing 1218 unique variables.
Conclusions:
- AD-Mapper effectively leverages semantic similarities in naming conventions for improved harmonization.
- The tool offers a robust solution for the long-standing challenge of AD cohort data harmonization.
- Facilitates more reliable and efficient data-driven research in Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181

